Illumina Launches Whole Genome Cancer Research Workflow

MT Newswires Live05-28

Illumina (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.

The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.

Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.

The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.

Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.

Price: 153.98, Change: +3.81, Percent Change: +2.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638769915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638769915","market":"hk","top_or_hot":-1,"title":"Illumina Launches Whole Genome Cancer Research Workflow","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.</p><p>The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.</p><p>Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.</p><p>The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.</p><p>Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.</p><p>Price: 153.98, Change: +3.81, Percent Change: +2.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Launches Whole Genome Cancer Research Workflow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Launches Whole Genome Cancer Research Workflow\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.</p><p>The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.</p><p>Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.</p><p>The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.</p><p>Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.</p><p>Price: 153.98, Change: +3.81, Percent Change: +2.54</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638769915","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638769915","pubTimestamp":1779976346,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Illumina  said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.Price: 153.98, Change: +3.81, Percent Change: +2.54","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina","BK4588":"碎股","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务"},"translate_title":"Illumina推出全基因组癌症研究工作流程","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5},"content_text":"Illumina (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.Price: 153.98, Change: +3.81, Percent Change: +2.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638769915","isCrawlerRequest":true}